The estimated Net Worth of Glenn R. Larsen is at least $621 millier dollars as of 28 August 2019. Glenn Larsen owns over 4,355 units of Anika Therapeutics stock worth over $184,058 and over the last 10 years he sold ANIK stock worth over $249,150. In addition, he makes $187,480 as Independent Director at Anika Therapeutics.
Sign up
Glenn Larsen ANIK stock SEC Form 4 insiders trading
Glenn has made over 1 trades of the Anika Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 4,355 units of ANIK stock worth $249,150 on 28 August 2019.
The largest trade he's ever made was selling 4,355 units of Anika Therapeutics stock on 28 August 2019 worth over $249,150. On average, Glenn trades about 436 units every 0 days since 2015. As of 28 August 2019 he still owns at least 7,590 units of Anika Therapeutics stock.
You can see the complete history of Glenn Larsen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Glenn Larsen biography
Dr. Glenn R. Larsen Ph.D. serves as Independent Director of the Company. He is currently President and Chief Executive Officer of Aquinnah Pharmaceuticals, Inc., a pharmaceutical company focused on the development of treatments for ALS and neurodegenerative diseases, which he co-founded in February 2014. He is also a co-founder and Chairman of the Board of Directors of 180 Therapeutics L.P., a clinical stage musculoskeletal drug development company focusing on treating fibrosis, which he co-founded in 2013. He previously served as Chief Scientific Officer and Executive Vice President of Research and Development at SpringLeaf Therapeutics, Inc., a producer of combination drug delivery devices, from 2010 through 2013 and as Chief Operating Officer and Executive Vice President of Research and Development, and as a member of the board of directors, at Hydra Biosciences, Inc., a biopharmaceutical company, from 2003 through 2010. During his prior employment at Wyeth (now Pfizer)/Genetics Institute, Dr. Larsen served in various drug discovery and development leadership positions, including Vice President Musculoskeletal Sciences where he directed Wyeth’s second-largest therapeutic area with responsibility for Enbrel, an anti-TNF therapeutic with multi-billion dollar annual sales used to treat rheumatoid arthritis and other diseases. Dr. Larsen received his Ph.D. in Biochemistry from Stony Brook University and a PMD from Harvard University Business School.
What is the salary of Glenn Larsen?
As the Independent Director of Anika Therapeutics, the total compensation of Glenn Larsen at Anika Therapeutics is $187,480. There are 10 executives at Anika Therapeutics getting paid more, with James Loerop having the highest compensation of $1,479,630.
How old is Glenn Larsen?
Glenn Larsen is 66, he's been the Independent Director of Anika Therapeutics since 2015. There are 2 older and 14 younger executives at Anika Therapeutics. The oldest executive at Anika Therapeutics Inc. is Joseph Bower, 81, who is the Independent Chairman of the Board.
Insiders trading at Anika Therapeutics
Over the last 21 years, insiders at Anika Therapeutics have traded over $58,649,775 worth of Anika Therapeutics stock and bought 34,227 units worth $758,329 . The most active insiders traders include Charles H Sherwood, Farmaceutici S.P.A. Fidia et Joseph H Capper. On average, Anika Therapeutics executives and independent directors trade stock every 47 days with the average trade being worth of $613,258. The most recent stock trade was executed by Cheryl R Blanchard on 11 March 2024, trading 64,480 units of ANIK stock currently worth $1,563,640.
What does Anika Therapeutics do?
who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an
What does Anika Therapeutics's logo look like?
Complete history of Glenn Larsen stock trades at Anika Therapeutics
Anika Therapeutics executives and stock owners
Anika Therapeutics executives and other stock owners filed with the SEC include:
-
James Loerop,
Executive Vice President - Business Development and Strategic Planning -
Thomas Finnerty,
Executive Vice President of Human Resources -
Dr. Cheryl Renee Blanchard Ph.D.,
Pres, CEO & Director -
David Colleran,
Exec. VP, Gen. Counsel & Corp. Sec. -
James Loerop,
Exec. VP of Bus. Devel. & Strategic Planning -
Michael L. Levitz,
Exec. VP, CFO & Treasurer -
Thomas M. Finnerty,
Exec. VP of HR -
Joseph Bower,
Independent Chairman of the Board -
Jeffery Thompson,
Independent Director -
Raymond Land,
Independent Director -
Glenn Larsen,
Independent Director -
Cheryl Blanchard,
President, Chief Executive Officer, Director -
Susan Vogt,
Independent Director -
Dr. Cheryl R. Blanchard,
Pres, CEO & Director -
Stephen Richard,
Independent Director -
John Henneman,
Independent Director -
David Colleran,
Executive Vice President, General Counsel, Secretary -
Michael Levitz,
Chief Financial Officer, Executive Vice President, Treasurer -
Anne Nunes,
VP of Operations -
Bart Bracy,
VP of Sales & Marketing of Americas -
James Chase,
Sr. VP of International Sales & Marketing -
Charles Sherwood III,
VP & Corp. Legal Counsel -
Mark Namaroff,
Exec. Director of Investor Relations & Corp. Communications -
Alexei Goraltchouk,
Sr. VP of Operations & Project Management -
Richard Hague,
Chief Commercial Officer -
Edward S. Ahn,
Chief Tech. & Strategy Officer -
Charles H Sherwood,
President and CEO -
Sylvia Cheung,
Chief Financial Officer -
Steve E Wheeler,
Director -
Dana M. Alexander,
Chief Operations Officer -
Stephen R. Mascioli,
Chief Medical Officer -
John C Moran,
Director -
Joseph G Darling,
President and CEO; Director -
Gary P Fischetti,
Director -
Sheryl L Conley,
Director -
John W Jr Sheets,
Chief Scientific Officer -
Farmaceutici S.P.A. Fidia,
10% owner -
Peter Litman,
VP, Business Development -
William J Knight,
Chief Financial Officer -
Harvey S Sadow,
Director -
William Mrachek,
V.P., Human Resources -
Samuel F Mckay,
Director -
Eugene A Davidson,
Director -
Francesco J Luppino,
Chief Operating Officer -
Carol A Barnett,
Chief Commercial Officer -
Kevin W Quinlan,
Chief Financial Officer -
Constance H Garrison,
VP Reg.,Clinical & Qlty. Sys. -
James E O Neill,
Chief Accounting Officer -
Carol A Toth,
Vice President, R & D -
Elizabeth Chen,
Sr. VP Mktg. & Bus. Dev. -
Anne Nunes,
SVP, Chief Operations Officer -
Stephen D. Griffin,
EVP, CFO and Treasurer -
Joseph H Capper,
Director -
William R Jellison,
Director